| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.0000092890.29552.22 |
| P8608 | Fatcat ID | release_2gg7xglvpncg7fwushht4mdecq |
| P953 | full work available at URL | https://www.ahajournals.org/doi/full/10.1161/01.CIR.0000092890.29552.22 |
| https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.0000092890.29552.22 | ||
| P698 | PubMed publication ID | 14517168 |
| P2093 | author name string | Akira Takeshita | |
| Kensuke Egashira | |||
| Hiroyuki Tsutsui | |||
| Jing Wen | |||
| Nobuhiro Suematsu | |||
| Tetsuya Shiomi | |||
| Hidenori Matsusaka | |||
| Masaki Ikeuchi | |||
| Shunji Hayashidani | |||
| P2860 | cites work | Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors | Q28573949 |
| The inflammatory response in myocardial infarction | Q34463456 | ||
| Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction | Q37527656 | ||
| Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop | Q40875349 | ||
| Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction | Q44243308 | ||
| Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction | Q45712799 | ||
| Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis | Q45871485 | ||
| Roles and relationship of macrophages and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the ischemic and reperfused rat heart | Q74045156 | ||
| Ventricular remodeling in a mouse model of myocardial infarction | Q74612209 | ||
| Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis | Q74844694 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| Cardiology and cardiovascular medicine | Q96320350 | ||
| gene therapy | Q213901 | ||
| ventricular remodeling | Q7920323 | ||
| P304 | page(s) | 2134-2140 | |
| P577 | publication date | 2003-09-29 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction | |
| Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction | |||
| P478 | volume | 108 |
| Q35047817 | Activation of endoplasmic reticulum stress response during the development of ischemic heart disease |
| Q40124831 | Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium |
| Q39957547 | Activation of the adenosine-A3 receptor stimulates matrix metalloproteinase-9 secretion by macrophages |
| Q36145827 | Agents targeting inflammation in heart failure |
| Q37974118 | Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing |
| Q48113765 | Anti-inflammatory therapies in myocardial infarction: failures, hopes, and challenges |
| Q38480164 | Antifibrotic therapies in the liver |
| Q47137916 | Apoptosis inhibitor of macrophage depletion decreased M1 macrophage accumulation and the incidence of cardiac rupture after myocardial infarction in mice |
| Q38985073 | Association between the monocyte chemoattractant protein-1 −2518G/A gene polymorphism and acute myocardial infarction patients among Egyptian population |
| Q37208204 | Blockade of NF-kappaB using IkappaB alpha dominant-negative mice ameliorates cardiac hypertrophy in myotrophin-overexpressed transgenic mice |
| Q42214940 | Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure |
| Q58757982 | Cardiac fibrosis: new insights into the pathogenesis |
| Q38046798 | Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends? |
| Q42125836 | Ccr1 deficiency reduces inflammatory remodelling and preserves left ventricular function after myocardial infarction |
| Q36800161 | Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. |
| Q37304014 | Chlorella 11-peptide inhibits the production of macrophage-induced adhesion molecules and reduces endothelin-1 expression and endothelial permeability |
| Q37351145 | Could interferon-gamma be a therapeutic target for treating heart failure? |
| Q53568084 | Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants. |
| Q41977722 | Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction |
| Q34722498 | Emergence of dendritic cells in the myocardium after acute myocardial infarction - implications for inflammatory myocardial damage |
| Q37190230 | Estrogen modulates the influence of cardiac inflammatory cells on function of cardiac fibroblasts |
| Q34201349 | Evaluation of Cardiac Function by Transthoracic Echocardiography in Subjects with ST-Segment Elevation Myocardial Infarction Following Primary Percutaneous Coronary Intervention according to Valsartan Dose: The Valsartan One Center Trial |
| Q90380756 | FPR1 gene silencing suppresses cardiomyocyte apoptosis and ventricular remodeling in rats with ischemia/reperfusion injury through the inhibition of MAPK signaling pathway |
| Q92513107 | Factors Associated with RANTES Concentration in Cardiovascular Disease Patients |
| Q48295375 | Fluorinated groups mediate the immunomodulatory effects of volatile anesthetics in acute cell injury. |
| Q38510554 | Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients. |
| Q36050486 | Genetic maneuvers to ameliorate ventricular function in heart failure: therapeutic potential and future implications |
| Q33605156 | Heart failure management: the present and the future |
| Q47144816 | Human Cardiac-Derived Stem/Progenitor Cells Fine-Tune Monocyte-Derived Descendants Activities toward Cardiac Repair |
| Q93106874 | Hyperoxia but not AOX expression mitigates pathological cardiac remodeling in a mouse model of inflammatory cardiomyopathy |
| Q47756011 | Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets |
| Q84984672 | Impaired post-infarction cardiac remodeling in chronic kidney disease is due to excessive renin release |
| Q34748917 | Increase of plasma IL-9 and decrease of plasma IL-5, IL-7, and IFN-γ in patients with chronic heart failure |
| Q26747421 | Inflammation and Inflammatory Cells in Myocardial Infarction and Reperfusion Injury: A Double-Edged Sword |
| Q38560476 | Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. |
| Q47734765 | Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities |
| Q58735426 | Inflammation in Right Ventricular Failure: Does It Matter? |
| Q35691449 | Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway |
| Q36198484 | Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications |
| Q38018808 | Inflammatory cytokines in heart failure: mediators and markers |
| Q48442504 | Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction |
| Q38187672 | Involvement of monocytes/macrophages as key factors in the development and progression of cardiovascular diseases. |
| Q27326691 | Kinetic mRNA Profiling in a Rat Model of Left-Ventricular Hypertrophy Reveals Early Expression of Chemokines and Their Receptors |
| Q33232390 | Leptin does not induce hypertrophy, cell cycle alterations, or production of MCP-1 in cultured rat and mouse cardiomyocytes |
| Q38190875 | Liver fibrosis and repair: immune regulation of wound healing in a solid organ |
| Q41871986 | Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice |
| Q63915886 | Macrophages and Cardiovascular Health |
| Q41985583 | Macrophages are required for neonatal heart regeneration |
| Q38044254 | Mechanisms and consequences of inflammatory signaling in the myocardium |
| Q28116119 | Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction |
| Q35552775 | Monocyte chemotactic protein-1 promotes inflammatory vascular repair of murine carotid aneurysms via a macrophage inflammatory protein-1α and macrophage inflammatory protein-2-dependent pathway |
| Q36820558 | Monocyte chemotactic protein-1 promotes the myocardial homing of mesenchymal stem cells in dilated cardiomyopathy |
| Q34873040 | Monocyte-specific Bcl-2 expression attenuates inflammation and heart failure in monocyte chemoattractant protein-1 (MCP-1)-induced cardiomyopathy |
| Q33942337 | Monocytes: protagonists of infarct inflammation and repair after myocardial infarction |
| Q35170119 | Mst1 inhibition rescues β1-adrenergic cardiomyopathy by reducing myocyte necrosis and non-myocyte apoptosis rather than myocyte apoptosis |
| Q51329978 | Murine Double Minute-2 Inhibition Attenuates Cardiac Dysfunction and Fibrosis by Modulating NF-κB Pathway After Experimental Myocardial Infarction. |
| Q35233087 | Myocardial production and release of MCP-1 and SDF-1 following myocardial infarction: differences between mice and man. |
| Q34356175 | Myofilament dysfunction contributes to impaired myocardial contraction in the infarct border zone |
| Q42479673 | Nano-scale treatment for a macro-scale disease: nanoparticle-delivered siRNA silences CCR2 and treats myocarditis |
| Q36478411 | Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion |
| Q34531894 | Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease |
| Q28383719 | Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis |
| Q39740814 | Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling. |
| Q37291291 | Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury |
| Q64967838 | Prostaglandin E2 and an EP4 receptor agonist inhibit LPS-Induced monocyte chemotactic protein 5 production and secretion in mouse cardiac fibroblasts via Akt and NF-κB signaling. |
| Q35060673 | Protease activated receptor-2 contributes to heart failure |
| Q44635832 | Protein disulfide isomerase increases in myocardial endothelial cells in mice exposed to chronic hypoxia: a stimulatory role in angiogenesis |
| Q39367362 | Proteins secreted by embryonic stem cells activate cardiomyocytes through ligand binding pathways |
| Q37536067 | Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications |
| Q50119083 | Role of Monocytes in Heart Failure and Atrial Fibrillation |
| Q38134311 | Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target |
| Q38206408 | Role of interleukin-6 in regulation of immune responses to remodeling after myocardial infarction |
| Q38106962 | Role of monocyte chemoattractant protein-1 in myocardial infarction |
| Q36526913 | Systemic inflammation in heart failure--the whys and wherefores |
| Q34873016 | Targeted cardiac expression of soluble Fas prevents the development of heart failure in mice with cardiac-specific expression of MCP-1. |
| Q35103051 | Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction |
| Q38120799 | Targeting the chemokines in cardiac repair. |
| Q79438590 | Tea catechins attenuate chronic ventricular remodeling after myocardial ischemia in rats |
| Q64357966 | Tefillin use induces remote ischemic preconditioning pathways in healthy men |
| Q38375149 | The duality of chemokines in heart failure |
| Q29615381 | The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions |
| Q47696973 | The infarcted myocardium solicits GM-CSF for the detrimental oversupply of inflammatory leukocytes |
| Q38154630 | The mononuclear phagocyte system in homeostasis and disease: a role for heme oxygenase-1. |
| Q38023271 | The role of TWEAK/Fn14 in cardiac remodeling |
| Q38003021 | Tissue microenvironments define and get reinforced by macrophage phenotypes in homeostasis or during inflammation, repair and fibrosis. |
| Q38068399 | Tissues use resident dendritic cells and macrophages to maintain homeostasis and to regain homeostasis upon tissue injury: the immunoregulatory role of changing tissue environments. |
| Q36587736 | Wnt11 Gene Therapy with Adeno-associated Virus 9 Improves Recovery from Myocardial Infarction by Modulating the Inflammatory Response |
Search more.